Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008

This study is currently recruiting participants.
Verified September 2012 by Oslo University Hospital
Sponsor:
Information provided by (Responsible Party):
Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT00982514
First received: September 22, 2009
Last updated: September 11, 2012
Last verified: September 2012

September 22, 2009
September 11, 2012
September 2009
December 2014   (final data collection date for primary outcome measure)
  • Clinical evident thrombosis [ Time Frame: 33 weeks ] [ Designated as safety issue: No ]
  • Asymptomatic central line-associated thrombosis [ Time Frame: 33 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00982514 on ClinicalTrials.gov Archive Site
Positive blood culture [ Time Frame: 33 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008
Thromboembolic Complications Related to Asparaginase in Children With ALL Treated According to NOPHO ALL 2008

The study will examine the prevalence of venous thromboembolism in children with acute lymphoblastic leukaemia treated in accordance with NOPHO ALL-2008. The investigators will prospectively study clinical symptomatic thromboses, asymptomatic central line-associated thromboses, and infections.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Oslo University Hospital, Department of Pediatrics

  • Thromboembolism
  • Acute Lymphoblastic Leukemia
Not Provided
  • Standard dose asparaginase
    Children who according to the protocol NOPHO ALL 2008 receive standard dose asparaginase
  • Reduced dose asparaginase
    Children who receive reduced dose asparaginase according to NOPHO ALL 2008
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
December 2014
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Acute lymphoblastic leukaemia,
  • Age 1 year to 16 years old,
  • Central line,
  • Protocol NOPHO ALL 2008.

Exclusion Criteria:

  • Refusal of participation,
  • Treated according to protocol other than NOPHO ALL 2008.
Both
1 Year to 16 Years
No
Contact: Ellen Ruud, MD PhD +47 23074560 ellen.ruud@rikshospitalet.no
Contact: Tonje Reiersen, MD +47 23070000 tonje.reiersen@rikshospitalet.no
Norway
 
NCT00982514
ASP NOPHO 2008
Yes
Oslo University Hospital
Oslo University Hospital
Not Provided
Principal Investigator: Ellen Ruud, MD PhD Oslo University Hospital
Oslo University Hospital
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP